Run­ning out of cash and cit­ed on fraud charges, Im­muno­Cel­lu­lar re­treats on PhI­II and cries for help

Things just keep get­ting worse and worse at Im­muno­Cel­lu­lar Ther­a­peu­tics $IMUC.

Three and a half years af­ter its lead can­cer vac­cine flopped in a Phase II glioblas­toma tri­al, some months af­ter its ac­coun­tant lev­eled a “go­ing con­cern” alert on the num­bers and just weeks af­ter one of its for­mer CEOs was cit­ed for a pho­ny stock pro­mo­tion scheme by the SEC, the floun­der­ing biotech has now been forced to call a halt to pa­tient as­sign­ments for its Phase III study af­ter run­ning short of cash to com­plete the job.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.